bluebird bio

About bluebird bio

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

Community guidelines: http://bit.ly/bbbGuidelines

Website	http://www.bluebirdbio.com
Employees	501-1,000 employees View all bluebird bio employees
Industry	Biotechnology
Location	455 Grand Union Blvd, Somerville, Massachusetts 02145, US
Founded	1993
Keywords	Gene Therapy, Sickle Cell Disease, Gene Addition, Cerebral Adrenoleukodystrophy, Beta-Thalassemia, Sickle Cell Disease, Gene Therapy
Technologies	Amazon SES Atlassian Cloud Bing Ads Drupal Google Analytics Google Tag Manager Greenhouse.io Leadfeeder Mailchimp Mandrill Microsoft Azure Hosting Microsoft Office 365 Mimecast Mobile Friendly MouseFlow New Relic Outlook Rackspace MailGun Remote Salesforce Sendgrid